Agios Pharmaceuticals
AGIO
72 hedge funds and large institutions have $242M invested in Agios Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 72 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$61.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.3M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$17.4M |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$14.4M |
| 5 |
Morgan Stanley
New York
|
+$7.81M |
Top Sellers
AGIO Hedge Fund Activity: Q3 2013 in Review
72 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q3 2013, worth a combined $242M.
Buyers outnumbered sellers: 72 funds opened new AGIO positions and 0 closed out — a net gain of 72 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $61.6M.
- 72 institutional investors held Agios Pharmaceuticals (AGIO) as of Q3 2013, up from 0 in Q2 2013.
- Funds reported $242M of Agios Pharmaceuticals stock for Q3 2013.
- 72 funds opened new Agios Pharmaceuticals positions in Q3 2013 and 0 closed out, a net change of +72 holders.
- The largest Agios Pharmaceuticals buyer in Q3 2013 was Fidelity Investments, an estimated $61.6M added.
Based on aggregated 13F filings for Q3 2013.